• 1
    Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011; 29: 551-565.
  • 2
    Freyer DR, Devidas M, La M, et al. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood. 2011; 117: 3010-3015.
  • 3
    Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010; 28: 648-654.
  • 4
    Malempati S, Gaynon PS, Sather H, La MK, Stork LC; Children's Oncology Group. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol. 2007; 25: 5800-5807.
  • 5
    Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M; Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group. Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer. 2009; 52: 591-595.
  • 6
    Nguyen K, Devidas M, Cheng SC, et al; Children's Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008; 22: 2142-2150.
  • 7
    Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010; 28: 2339-2347.
  • 8
    von Stackelberg A, Völzke E, Kühl JS, et al; ALL-REZ BFM Study Group. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. Eur J Cancer. 2011; 47: 90-97.
  • 9
    Bonilla M, Gupta S, Vasquez R, et al. Predictors of outcome and methodological issues in children with acute lymphoblastic leukaemia in El Salvador. Eur J Cancer. 2010; 46: 3280-3286.
  • 10
    Pui CH, Sandlund JT, Pei D, et al; Total Therapy Study XIIIB at St Jude Children's Research Hospital. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004; 104: 2690-2696.
  • 11
    Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360: 2730-2741.
  • 12
    Fronkova E, Mejstrikova E, Avigad S, et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia. 2008; 22: 989-997.
  • 13
    Quintana Y, Patel AN, Naidu PE, Howard SC, Antillon FA, Ribeiro RC. POND4Kids: a web-based pediatric cancer database for hospital-based cancer registration and clinical collaboration. Stud Health Technol Inform. 2011; 164: 227-231.
  • 14
    Ayoub L, Fú L, Peña A, et al. Implementation of a data management program in a pediatric cancer unit in a low income country. Pediatr Blood Cancer. 2007; 49: 23-27.
  • 15
    Gupta S, Antillon FA, Bonilla M, et al. Treatment-related mortality in children with acute lymphoblastic leukemia in Central America. Cancer. 2011; 117: 4788-4795.